Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8039627 | NEUROCRINE | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
Apr, 2031
(7 years from now) | |
US10065952 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(13 years from now) | |
US10844058 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(13 years from now) | |
US10851103 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(13 years from now) | |
US10851104 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(13 years from now) | |
US10919892 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(13 years from now) | |
US10906903 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(13 years from now) | |
US10906902 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(13 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8357697 | NEUROCRINE | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
Nov, 2027
(4 years from now) | |
US11040029 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(14 years from now) | |
US10912771 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(14 years from now) | |
US10993941 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(14 years from now) | |
US10857148 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(14 years from now) | |
US10874648 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(14 years from now) | |
US10857137 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(14 years from now) | |
US10952997 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(14 years from now) | |
US11026939 | NEUROCRINE | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
Sep, 2038
(15 years from now) | |
US11311532 | NEUROCRINE | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
Sep, 2038
(15 years from now) | |
US11026931 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Aug, 2039
(16 years from now) | |
US10940141 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Aug, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 11, 2022 |
NCE-1 date: 2021-04-11
Market Authorisation Date: 11 April, 2017
Treatment: Treatment of tardive dyskinesia; Method of treating tardive dyskinesia while avoiding concomitant use of a strong cyp3a4 inducer; Method of administering valbenazine while avoiding concomitant use of ...
Dosage: CAPSULE;ORAL
59
United States
20
Japan
13
China
12
Australia
11
Canada
10
Korea, Republic of
10
EA
9
Mexico
8
Philippines
6
Singapore
6
European Union
5
Morocco
4
Brazil
4
Israel
3
Poland
3
Denmark
3
Spain
3
Portugal
2
Slovenia
2
Taiwan
2
Lithuania
2
RS
2
Croatia
2
Hungary
1
Saudi Arabia
1
Chile
1
Malaysia
1
Argentina
1
Colombia
1
Tunisia
1
Jordan
1
Cyprus
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic